Last reviewed · How we verify
NCT03809247
Microbial Diversity of Pancreatic Diseases
trial in Pancreatic Cancer in 330 participants. Status unknown.
30 July 2024
Quick facts
| Lead sponsor | Ruijin Hospital |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 330 |
| Start date | 1 February 2019 |
| Primary completion | 30 July 2024 |
| Estimated completion | 31 December 2025 |
| Sites | 1 location across China |
Conditions studied
- Pancreatic Cancer — all drugs for Pancreatic Cancer →
- Pancreatic Disease — all drugs for Pancreatic Disease →
Sponsor
Ruijin Hospital
Who can join
Adults 3 to 85, any sex, with Pancreatic Cancer or Pancreatic Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study plans to analyze the digestive flora structure of the group of patients with pancreatic cancer. The investigators compared the microflora of pancreatic cancer with other pancreatic diseases and healthy people，in order to obtatin the information of microbial community difference among the different groups. Finally，the investigators hope to identify the potential biomarker and pathogenic mechanisms that causes the onset and progression of pancreatic diseases.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
The role of microbiome in pancreatic cancer.
Li JJ, Zhu M, Kashyap PC, Chia N, et al · · 2021 · cited 39× · PMID 34455517 · DOI 10.1007/s10555-021-09982-2 -
Pancreatic Cancer and Gut Microbiome-Related Aspects: A Comprehensive Review and Dietary Recommendations.
Sobocki BK, Kaźmierczak-Siedlecka K, Folwarski M, Hawryłkowicz V, et al · · 2021 · cited 30× · PMID 34959977 · DOI 10.3390/nu13124425 -
Implications of the microbiome in the development and treatment of pancreatic cancer: Thinking outside of the box by looking inside the gut.
Yu Q, Jobin C, Thomas RM. · · 2021 · cited 21× · PMID 33418277 · DOI 10.1016/j.neo.2020.12.008 -
Disordered Gut Microbiota in Children Who Have Chronic Pancreatitis and Different Functional Gene Mutations.
Wang W, Xiao Y, Wang X, Zhou Y, et al · · 2020 · cited 17× · PMID 32352720 · DOI 10.14309/ctg.0000000000000150 -
Research Progress of Pancreas-Related Microorganisms and Pancreatic Cancer.
Zhang W, Zhang K, Zhang P, Zheng J, et al · · 2020 · cited 13× · PMID 33520714 · DOI 10.3389/fonc.2020.604531 -
A combination of faecal and intratumour microbial community profiling reveals novel diagnostic and prognostic biomarkers for pancreatic tumours.
Wang W, Qian C, Wang T, Jiang Y, et al · · 2024 · cited 6× · PMID 38822473 · DOI 10.1002/ctm2.1726 -
From Microbiome to Malignancy: Unveiling the Gut Microbiome Dynamics in Pancreatic Carcinogenesis.
Sulekha Suresh D, Jain T, Dudeja V, Iyer S, et al · · 2025 · cited 3× · PMID 40243755 · DOI 10.3390/ijms26073112 -
Strategic modulation of the gastrointestinal microbiome to enhance pancreatic cancer immunotherapy.
Jagwani S, Musumeci L, Flores L, Mackenzie GG, et al · · 2025 · PMID 41203044 · DOI 10.1016/j.drudis.2025.104528
Verify or expand the search:
- PubMed search for NCT03809247
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Pancreatic Cancer
Currently open trials in the same condition.
- NCT07126158 — Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma · Phase 2 · recruiting
- NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
- NCT07439757 — AI-Powered Precision Decision-Making for Pancreatic Diseases · recruiting
- NCT07409272 — A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherap · Phase 3 · recruiting
- NCT07236177 — B-GLUCANCER2 : A Pilot Study Evaluating a New Method for Cancer Detection by Measuring the Activity of Different Glycosi · EARLY_PHASE1 · recruiting
Other Ruijin Hospital trials
Trials by the same sponsor.
- NCT07589361 — Safety and Efficacy of Vertebral Body-Sparing Craniospinal Irradiation With Proton Therapy in Pediatric Tumors · not yet recruiting
- NCT07449507 — Partially Hydrolyzed Whey Protein Formula for Infants With Mild Allergy · NA · not yet recruiting
- NCT07496385 — Clinical Study on the Efficacy of Subglottic Suction in Mechanically Ventilated Patients Guided by Bedside Ultrasound · NA · not yet recruiting
- NCT07511114 — A Study Comparing C Pola R-CHP+X With CR-CHOP in the Treatment of Previously Untreated DEL Under the Guidance of Genotyp · Phase 3 · not yet recruiting
- NCT07514169 — The Efficacy and Safety of Pola-ZR-Glo in Older Treatment-naive Patients With LBCL · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03809247 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ruijin Hospital
- Last refreshed: 15 June 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03809247.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing